Lannett (LCI) Announces Positive Results from C-Topical Phase 3

October 27, 2016 6:51 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Lannett Company, Inc. (NYSE: LCI) announced successful results from a placebo-controlled Phase III clinical study evaluating C-Topical (cocaine hydrochloride solution) 4% and 10% as a local anesthetic for diagnostic procedures or surgeries on or through the inside of the nose.

The 646-patient study met all primary clinical endpoints of the trial and had a statistically significant treatment effect for both the 4% and the 10% solutions. Toxicology and pharmacokinetic studies are ongoing and expected to be completed by year end.

"We are very pleased by the positive Phase III results for C-Topical," said Arthur Bedrosian, chief executive officer of Lannett. "Upon the successful completion of the toxicology and pharmacokinetic studies for C-Topical, our plan is to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) during the summer of 2017. The success of C-Topical as a local anesthetic solution suggests that it could become an important option for use by otolaryngologists (ear, nose and throat) physicians and specialists for office-based and in-patient procedures."

C-Topical is administered by means of cotton applicators, called pledgets.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA

Add Your Comment